Senseonics Holdings Inc. (SENS)
NASDAQ: SENSHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SENS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $439.34M
- EPS (TTM)
- -$2.27
- Dividend yield
- None
- 52-week range
- 4.79 – 13.98
- Day range
- 7.93 – 8.95
- Volume / Avg
- 1.39M / 821.73K
- Beta
- —
- Shares outstanding
- 54.78M
52-week range
SENS stock today
On Nov 20, SENS ended the session at $8.02, shedding $0.885 (9.94%), versus the S&P 500's 3.70% decline. Shares are 42.6% below their 52-week high of $13.98, set on Nov 10, 2026 and 67.4% above the 52-week low of $4.79, in the middle of the past year's range. SENS is up 45.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 49.9%.
Senseonics has posted a net loss over the last twelve months (EPS of -$2.27), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Senseonics
Company profileSenseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Dr. Timothy T. Goodnow Ph.D.
- Headquarters
- Germantown, MD
- Employees
- 130
- Website
- senseonics.com
Financial highlights
Full financialsIn fiscal 2025, Senseonics generated $35.3 million in revenue, up 56.9% from fiscal 2024, its 5th consecutive year of revenue growth. Senseonics reported a net loss of $69.1 million, compared with a loss of $78.6 million a year earlier. Gross margin was 44.7% (up from 2.4%) and operating margin -193.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $35.26M | $22.47M | $22.39M | $16.39M | $13.68M |
| Growth | +56.89% | +0.37% | +36.62% | +19.85% | +176.32% |
| Net income | $-69.10M | $-78.60M | $-60.40M | $142.10M | $-302.47M |
| EPS (diluted) | $-1.66 | $-2.50 | $-0.11 | $-0.11 | $-0.72 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$15.08+88.03%
- Strong buy 0
- Buy 4
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.43 vs $-0.49
- Surprise
- +12.24%
SENS news
All SENS news- BBNX & SENS Launch Eversense 365 Integration With iLet Bionic PancreasNasdaqSENS, BBNX, ISRG, GKOS
- Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas IntegrationGlobeNewswireBBNX, SENS
- Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas IntegrationGlobeNewswireSENS, BBNX
- Senseonics (SENS) Q3 2026 Earnings Call TranscriptNasdaqSENS, BF.A
- Senseonics hits 52-week high as Raymond James upgrades on Q3 beat and raiseSeeking Alpha
- Senseonics surges 18% in premarket on Q3 beat, raised revenue outlookSeeking Alpha
- Senseonics Shares Rise 12% As Q3 Revenue Jumps 140%; FY26 Outlook RaisedNasdaqSENS, MKC.V
- Senseonics targets $68M-$70M 2026 revenue as Freedom CGM human testing beginsSeeking Alpha
Senseonics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MDXGMiMedx Group Inc | 3.05 | -1.93% | $445.07M | vs SENS |
| ANGOAngioDynamics Inc. | 10.81 | +0.46% | $454.61M | vs SENS |
| SIShoulder Innovations Inc. | 20.15 | -0.79% | $421.58M | vs SENS |
| CARLCarlsmed Inc. | 17.42 | +1.16% | $477.38M | vs SENS |
| MOBIMobia Medical Inc. | 11.85 | -0.08% | $394.50M | vs SENS |
| RCELAvita Medical Inc. | 15.62 | -2.31% | $494.96M | vs SENS |
| CERSCerus Corporation | 1.85 | -2.63% | $373.62M | vs SENS |
| BWAYBrainsWay Ltd. ADR | 8.48 | -2.86% | $341.35M | vs SENS |
Indexes, lists and sector
Senseonics stock FAQ
What is Senseonics's stock price today?
SENS last traded at $8.02 as of Nov 20, 4:00 PM EST, down 9.94% on the day. Prices are delayed at least 15 minutes.
Does Senseonics pay a dividend?
No. Senseonics does not currently pay a regular cash dividend.
Who is Senseonics's CEO?
Dr. Timothy T. Goodnow Ph.D. is the chief executive officer of Senseonics Holdings Inc., which has about 130 employees.
Has SENS ever split its stock?
Yes. The most recent SENS stock split was a 1-for-20 split on Oct 20, 2025.
What is the SENS 52-week high?
The 52-week high for SENS is $13.98 and the 52-week low is $4.79. The stock is currently 42.6% below its high.